Andrew Thomson
I am CEO + co-founder of Modulate Bio, advancing a new generation of small molecule medicines to treat tremors, epilepsy and other brain disorders.
I graduated Harvard Business School in 2024, and am now a Harvard Blavatnik Fellow in Life Sciences Entrepreneurship. For 5 years I was a life sciences consultant at Charles River Associates, where I led strategy projects in biopharma, including M+A due diligence, corporate strategy and commercial opportunity assessments.
At Brown University, I studied biology and developed an engineering technique in Jeffrey Morgan's lab robotically building human blood vessels, which resulted in 4 patents and 2 publications.
